RNA sequence could help doctors to tailor unique prostate cancer treatment programs: Drs. Wyatt and Collins

Date Posted: 
2014-08-26

Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the open access journalGenome Biology. Because a tumor’s RNA shows the real time changes a treatment is causing, the authors think this could be a useful tool to aid diagnosis and predict which treatment will most benefit individual cancer patients.

Drs. Colin Collins and Alexander Wyatt, and other researchers from the Vancouver Prostate Centre at the Vancouver Coastal Health Research Institute, matched 25 patients’ treatment outcomes with the RNA sequence of their prostate cancer tumors. They suggest that similarities between the RNA of some of the patients’ tumors could open up new avenues of treatment.

Prostate cancer is the fourth most common cancer worldwide, but can be effectively managed. Doctors normally recommend a combination of therapies, because patients’ reaction to treatment varies considerably. The side-effects of these treatments can be significant, so current research is focused around precision medicine – classifying patients on their tumor’s molecular changes, and only giving them the treatments that are expected to be most effective.

To investigate variations between the highest risk cases of prostate cancer, researchers conducted a range of genomic analyses, including sequencing the RNA in 25 patients’ prostate tumors. The RNA molecules direct which proteins the cell produces, so the RNA sequences show how tumor cells behave differently to normal cells.

Alexander Wyatt, Vancouver Prostate Centre, says: “Most genomic sequencing studies have focused on the DNA, which gives us important information about a tumor’s history. In our study we examined RNA, which tells us which genes are being used and are disrupted at the time the tumor was collected.”

They then matched up this data with the detailed follow-up information that they had for each of the patients. They were then able to see what sequence disruptions were associated with a positive reaction to different therapies, and they believe this could aid personalized medicine.

Dr. Wyatt says: “We were surprised by the sheer number of genomic differences between patients. This complexity may help explain why patients respond differently to treatment, and why some tumors grow faster than others. The more we understand tumor-to-tumor variability, the closer we come to accurately tailoring a patient’s management specifically for his own tumor. Overall, this is a very exciting time for cancer research, as global sequencing efforts mean we are advancing towards precision oncology.”

Another potential use of this information is that in certain groups, there was a similarity in the type of genes and pathways that were disrupted in the tumours. This might indicate an underlying cancer mechanism that could be exploited to create new cancer treatments.

Dr. Wyatt says: “Despite the enormous complexity between patients at the individual gene level, when we examined the functions of affected genes, clear commonalities between groups of patients emerged. Ultimately it may be possible to exploit this convergent biology.”

Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
Alexander W Wyatt, Fan Mo, Kendric Wang, Brian McConeghy, Sonal Brahmbhatt, Lina Jong, Devon M Mitchell, Rebecca L Johnston, Anne Haegert, Estelle Li, Janet Liew, Jake Yeung, Raunak Shrestha, Anna Lapuk, Andrew McPherson, Robert Shukin, Robert H Bell, Shawn Anderson, Jennifer Bishop, Antonio Hurtado-Coll, Hong Xiao, Arul M Chinnaiyan, Rohit Mehra, Dong Lin, Yuzhuo Wang, Ladan Fazli, Martin E Gleave, Stanislav V Volik and Colin C Collins
Genome Biology 2014 15: 426

Media Contacts

Shane Canning, Media Officer
BioMed Central
T: +44 (0)20 3192 2243
E: shane [dot] canningatbiomedcentral [dot] com

Faydra Aldridge, Director, Stakeholder Relations & Public Affairs
Vancouver Coastal Health Research Institute
T: +1 604 875 4111
E: faydra [dot] aldridgeatvch [dot] ca

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

VPC Terry Fox team 2016

Terry Fox Run: Sunday September 16, 2018

On Sunday September 16, the fundraising Terry Fox walk/run/ride is taking place across Canada.  We are grateful for our  grant support provided by The Terry Fox Foundation and Terry Fox Research Institute continously since 1998 - click here to donate to our team (opens in new window)

 

Vancouver

18th Annual Pacific Northwest Prostate Cancer Conference: Sat Sept 22, 2018

The 18th Annual Pacific Northwest Prostate Cancer Conference for patients, their families and health care professionals will be held in Vancouver on Saturday September 22, from 8 AM to 4 PM.  Click here for further details and to purchase tickets ($30, includes lunch). (Opens in new window)

 

Employment

Work at the Vancouver Prostate Centre

Thursday, July 26, 2018

Dr. Gleave awarded the 2018 Dr. Chew Wei Memorial Prize in Cancer Research

Dr. Gleave
Tuesday, May 29, 2018

Three VPC trainees receive 2018 VCHRI Rising Star Awards

2018 Rising Star Awardees
DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.